Picture of Intocell logo

287840 — Intocell Cashflow Statement

0.000.00%
kr flag iconLast trade - 00:00
HealthcareHighly SpeculativeSmall CapSucker Stock

Annual cashflow statement for Intocell, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

2021
December 31st
2023
December 31st
2024
December 31st
2025
December 31st
Period Length:12 M12 M12 M12 M
Source:PROSPECTUSPROSPECTUSPROSPECTUSAnnual Audited Accounts
Standards:
IFRS
IFRS
IFRS
IFRS
Status:FinalFinalFinalFinal
Net Income/Starting Line—-16,775-9,913-10,603
Depreciation
Amortisation
Non-Cash Items—-57.2280576
Unusual Items
Other Non-Cash Items
Changes in Working Capital—-7701,917640
Change in Accounts Receivable
Change in Other Assets
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities0-16,774-7,046-8,626
Capital Expenditures—-1,072-1,237-1,304
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items—9,9224,927-12,672
Sale/Maturity of Investment
Change in Net Investments
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities—8,8503,690-13,975
Financing Cash Flow Items——1500
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities—10,0834,35627,618
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash—2,1751,0125,016